NeuroMetrix Adds Artificial Intelligence, Coaching and New Therapy Option to Quell 2.0 For Personalized Pain Relief
January 07 2019 - 07:00AM
NeuroMetrix Inc. (Nasdaq: NURO) today unveiled its smartest,
smallest and most powerful wearable therapeutic to date. With new
features seen for the first time at CES, the recently launched
Quell® 2.0 is 50% smaller, yet 20% more powerful than its
predecessor. The Company will introduce new functionality at
CES that includes updates to the Quell app like coaching that helps
users achieve the best possible outcomes. It also takes Pain Tech
to a new level with an Intensive Therapy option and is the first
wearable technology to utilize machine learning to deliver
unprecedented personalization for the treatment of chronic pain.
Named a CES® 2019 Innovation Awards Honoree, in the Fitness,
Sports and Biotech product category, Quell is a 100% drug-free
system that uses prescription strength nerve-stimulation technology
to block chronic pain. Aspiring to be part of the solution to the
chronic pain crisis, Quell is designed for multiple types and
sources of pain and has been shown in clinical studies to relieve
chronic pain. It can be seen during CES January 8-11, 2019
at the Sands Expo Center, Hall C Booth #43810.
How It Works
A Class II medical device, Quell 2.0 is an advanced form of
transcutaneous electrical nerve stimulation (TENS). The device is
worn on the leg, regardless of the site of pain, and sends neural
pulses to the brain that trigger a natural pain relief response in
the central nervous system.
Worn in a breathable soft, flexible band, the Quell device has a
credit card sized footprint so that it is discreet and comfortable
under clothing. Quell 2.0 is powered by a proprietary
neurostimulation microchip. It is 50% smaller than the
original Quell device, yet it outputs up to 20% more electrical
power. Quell technology is up to 10x more powerful than
typical OTC TENS devices.*
A new Intensive Therapy option will be added to Quell 2.0 that
delivers intensive nerve stimulation concentrated into a 15-minute
session. This therapy option will give Quell users another
choice for obtaining pain relief, one that may act faster than
standard Quell therapy. No other wearable TENS device has the
electrical power to provide Intensive Therapy. The Quell
Relief app makes using both Intensive Therapy and Standard Therapy
seamless, to achieve the best possible pain relief for each
individual.
With a typical battery life of up to 25 hours Quell 2.0 is the
only wearable pain device FDA cleared for day and nighttime use and
has been designed for multiple types and sources of chronic pain.
After a simple set up, Quell will automatically deliver therapy,
and is so smart that it will adapt therapy throughout the day. For
the best results, it is advised that Quell be used daily for a
minimum of 3 therapy sessions per day. In a published clinical
study, 4 out of 5 users reported improvements in their pain.**
Pain Relief Under Control
The Quell Relief App has also received a significant upgrade.
The newly added Therapy Coach combines goal setting, real-time
feedback, educational content, and motivational messages to
encourage daily use of Quell to help new users maximize results.
Additionally, its intuitive design allows users to personalize
therapy to their individual needs and track progress, including
measurable outcomes of success such as reported pain levels and
changes in sleep and gait, using the accelerometer in the
device.
Unprecedented Personalization Through AI
Quell 2.0 is packed with sophisticated therapeutic intelligence,
delivering on the promise of AI. These algorithms are derived from
the application of machine learning to millions of data points from
over 70,000 chronic pain suffers in the Quell Health Cloud™. The
process evaluates demographics, health conditions, pain levels and
characteristics, device utilization and objective measures of
sleep, activity and gait from Quell users to power truly
personalized treatment.
Quell is smart enough to adjust a user’s therapy based on manual
intensity changes, body position, and sleep movements. Quell
can even adapt to changes in the local weather, providing user
alerts and the option to increase dosage if the weather is
predicted to change in a way that affects their pain!
Making a Dent in the Opioid Crisis
An estimated 100 million Americans are living with some form of
chronic pain, costing an estimated $635 billion per year for
treatments and lost economic output. Recent research shows that
people living with chronic pain feel stigmatized by the opioid
crisis and are looking for alternative treatments.*** Pain Tech
such as Quell has an important role to play in helping people
reclaim their life from chronic pain.
“Since first launching Quell in 2015, over 180,000 individuals
living with chronic pain have experienced its patented
neurotechnology,” said Shai N. Gozani, M.D., Ph.D., President and
CEO of NeuroMetrix. “The Quell 2.0 device and the new features and
technology we are unveiling at CES are a direct result of customer
feedback and our latest research. Quell has been designed to
offer a long-term solution for chronic pain suffers seeking
non-pharmacological pain relief options.”
Availability
To learn more about Quell 2.0 visit QuellRelief.com. The
AI powered capabilities, Intensive Therapy option and Therapy Coach
will be commercially available later in 2019.
About NeuroMetrix
NeuroMetrix is a commercial stage, innovation-driven healthcare
company combining neurostimulation and digital medicine to address
chronic health conditions including chronic pain, sleep disorders,
and diabetes. The Company has two primary products. Quell is an
over-the-counter wearable therapeutic device for chronic pain.
DPNCheck® is a rapid point-of-care test for diabetic neuropathy
which is the most common long-term complication of Type 2 diabetes.
For more information, please visit http://www.neurometrix.com.
NeuroMetrix CES Media Contact: Cara Morgan /
Tandem Marketing Communicationscaramorgan@tandemcomms.com | (713)
829-1794
NeuroMetrix Investor Relations: Thomas T.
Higgins, 781-314-2761 SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com
* Comparison to leading OTC TENS devices, based on retail sales
data. Maximum sustained energy when used as directed.** Journal of
Pain Research 2016;(9):469-479. Based on 60 days of product
use. Results may vary.*** NeuroMetrix.
(2018). Flipping the Script: Living with Chronic Pain amid the
Opioid Epidemic.
Source: NeuroMetrix, Inc.
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/55b98405-33c4-4e33-a942-bbb5b40e8f74
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Feb 2024 to Mar 2024
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Mar 2023 to Mar 2024